Business
Agenus Reports Q1 2025 Financial Results and Key Business Updates
LEXINGTON, Mass., May 12, 2025--Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program.
About this update from Agenus Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones","length":76,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Near-Term Capital Transaction Poised to Bolster Liquidity","length":57,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":249,"olType":false},{"type":"text","content":"LEXINGTON, Mass., May 12, 2025--(BUSINESS WIRE)--Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program.","length":366,"tagName":"p"},{"type":"text","content":""The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and fuels our unwavering commitment to delivering this combination to patients," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "With expanded datasets, key leadership appointments, and the FDA’s renewed focus on accelerating cures and meaningful treatments, Agenus is entering a pivotal phase—advancing toward regulatory engagement with financial discipline and a sharp focus on bringing innovative immunotherapies to individuals living with cancer."","length":614,"tagName":"p"},{"type":"text","content":"Key Highlights from Q1 2025","length":27,"tagName":"p"},{"type":"text","content":"New Data:","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BOT/BAL continues to demonstrate robust and durable responses across microsatellite stable (MSS) "cold tumors" where current immuno-oncology treatments have historically failed. At American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, new data highlighted the activity and safety profile in both multiple mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors in neoadjuvant and later line treatment settings.","length":489,"tagName":"p","attribs":...